Skip to main content
TECON BIOLOGY Co.LTD logo

TECON BIOLOGY Co.LTD — Investor Relations & Filings

Ticker · 002100 ISIN · CNE000001PZ9 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,493 across all filing types
Latest filing 2022-12-05 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002100

About TECON BIOLOGY Co.LTD

https://www.tcsw.com.cn

TECON BIOLOGY Co.LTD operates an integrated industrial chain focused on animal health and nutrition. The company specializes in the research, development, and manufacturing of veterinary biological products, including a comprehensive range of vaccines and diagnostic reagents for livestock. Its operations encompass the production of high-quality animal feed and the management of large-scale breeding programs, with a primary focus on pig farming and meat processing. By leveraging advanced biotechnology and standardized production systems, the company provides comprehensive solutions for livestock management and food safety. Key activities include the formulation of specialized animal nutrition products and the implementation of rigorous biosecurity protocols across its facilities to ensure the quality and reliability of its agricultural outputs.

Recent filings

Filing Released Lang Actions
第七届监事会第二十二次（临时）会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the supervisory board (监事会) of Tian Kang Bio Co., Ltd. regarding the approval of a proposal to use temporarily idle raised funds for cash management. It includes voting results and references a related announcement (2022-080) for details. The document is short (831 characters) and serves as an official announcement of a board meeting decision rather than a full report or financial statement. It does not contain financial data or detailed management discussion. It is not a full Annual Report, Interim Report, or Earnings Release. It is not a regulatory certification or officer attestation. The content fits best with a Regulatory Filing (RNS) as a general regulatory announcement about company decisions and compliance with disclosure requirements.
2022-12-05 Chinese
关于归还用于暂时补充流动资金的闲置募集资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Tian Kang Bio Co., Ltd. regarding the repayment of temporarily used idle raised funds for working capital. It references a previous announcement about the use of idle raised funds and confirms the full repayment within the approved period. The document is short (701 characters) and serves as a formal notification about the status of capital usage and repayment, not a detailed financial report or audit. It fits the category of Capital/Financing Update (CAP) as it deals with the company's financing activities related to raised funds and their usage.
2022-12-05 Chinese
独立董事专项意见
Audit Report / Information Classification · 90% confidence The document is a special opinion from independent directors regarding the use of temporarily idle raised funds for cash management. It references regulatory guidelines and company rules but does not contain financial statements or detailed financial data. The document is short (661 characters) and appears to be a formal opinion or certification rather than a full report. It is not an annual report, interim report, or earnings release. It is not a regulatory announcement or voting result. The content fits best as an Audit Report / Information (AR) type, as it involves an independent directors' special opinion on compliance and fund usage, which aligns with audit or regulatory compliance reporting rather than a full financial report or announcement. FY 2022
2022-12-05 Chinese
第七届董事会第三十四次（临时）会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the company's 34th interim meeting of the 7th Board of Directors. It includes details about the meeting date, attendance, agenda items, voting results, and references to related announcements and opinions published elsewhere. There is no financial data or report content itself, but rather a disclosure of board decisions and related procedural information. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management.
2022-12-05 Chinese
关于使用部分暂时闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Tian Kang Biological Co., Ltd. regarding the use of temporarily idle raised funds for cash management. It details the approval by the board and supervisory committee, the amount of funds raised through a non-public stock issuance, the investment projects funded, the amount of idle funds, and the company's plan to invest these idle funds in safe, liquid, principal-guaranteed financial products. It includes opinions from the board, independent directors, supervisory board, and the sponsoring institution. The document is a formal disclosure about the company's use of idle raised funds for cash management, which is a financing update related to the use of raised capital. It is not a full financial report, audit report, or earnings release. It is not a regulatory filing or a report publication announcement since it contains substantive information about the use of funds and approvals. Therefore, the document fits best under Capital/Financing Update (CAP).
2022-12-05 Chinese
中信建投证券股份有限公司关于天康生物股份有限公司使用部分暂时闲置募集资金进行现金管理的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from a sponsoring securities company regarding the use of temporarily idle raised funds by Tian Kang Bio Co., Ltd. for cash management. It includes specifics about the raised funds, usage plans, cash management products, risk controls, and approvals from the board, independent directors, and supervisory board. The document is a formal verification or audit opinion related to the use of funds, not a full annual or interim financial report. It does not contain comprehensive financial statements or earnings data but focuses on compliance and verification of fund usage. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and verification opinions related to accounting and fund usage, excluding full annual reports or earnings releases. FY 2022
2022-12-05 Chinese

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.